The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial)

Judi van Diessen, Dirk De Ruysscher, Jan-Jakob Sonke, Eugene Damen, Karolina Sikorska, Bart Reymen, Wouter van Elmpt, Gunnar Westman, Gitte Fredberg Persson, Edith Dieleman, Hedvig Bjorkestrand, Corinne Faivre-Finn, Jose Belderbos*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)166-173
Number of pages8
JournalRadiotherapy and Oncology
Volume131
DOIs
Publication statusPublished - Feb 2019

Keywords

  • Dose-escalation
  • Non-small cell lung cancer
  • PET-boost
  • Toxicity
  • Dose painting
  • POSITRON-EMISSION-TOMOGRAPHY
  • CONFORMAL RADIATION-THERAPY
  • CONCURRENT CHEMOTHERAPY
  • NSCLC PATIENTS
  • ACCELERATED RADIOTHERAPY
  • RADICAL RADIOTHERAPY
  • REGIONAL FAILURE
  • TUMOR VOLUME
  • SURVIVAL
  • CHEMORADIOTHERAPY

Cite this

van Diessen, J., De Ruysscher, D., Sonke, J-J., Damen, E., Sikorska, K., Reymen, B., van Elmpt, W., Westman, G., Persson, G. F., Dieleman, E., Bjorkestrand, H., Faivre-Finn, C., & Belderbos, J. (2019). The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial). Radiotherapy and Oncology, 131, 166-173. https://doi.org/10.1016/j.radonc.2018.09.019